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Abstract
Multi-modal neuroimaging and biomarker data provide exciting opportunities to enhance our 
understanding of phenotypic characteristics associated with complex disorders. This study focuses 
on integrative analysis of structural MRI data and proteomic data from an RBM panel to examine 
their predictive power and identify relevant biomarkers in a large MCI/AD cohort. MRI data 
included volume and thickness measures of 98 regions estimated by FreeSurfer. RBM data 
included 146 proteomic analytes extracted from plasma and serum. A sparse learning model, 
elastic net logistic regression, was proposed to classify AD and MCI, and select disease-relevant 
biomarkers. A linear support vector machine coupled with feature selection was employed for 
comparison. Combining RBM and MRI data yielded improved prediction rates: HC vs AD 
(91.9%), HC vs MCI (90.5%) and MCI vs AD (86.5%). Elastic net identified a small set of 
meaningful imaging and proteomic biomarkers. The elastic net has great power to optimize the 
sparsity of feature selection while maintaining high predictive power. Its application to multi-
modal imaging and biomarker data has considerable potential for discovering biomarkers and 
enhancing mechanistic understanding of AD and MCI.
1 Introduction
Multi-modal neuroimaging data, such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET), studied independently or coupled with other biomarker data 
(e.g., cerebrospinal fluid (CSF) and neuropsychological assessments), have been shown to 
be sensitive to Alzheimer’s Disease (AD) and mild cognitive impairment (MCI, thought to 
be the prodromal stage of AD). Although recent studies reported promising prediction rates 
by integrating these multi-modal data [7,10,16], few were focused on identifying a small set 
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of disease relevant biomarkers [13] to enhance our understanding of phenotypic 
characteristics and underlying mechanisms associated with complex disorders.
With these observations, this paper has the following aims: (1) investigate the predictive 
power of a new set of proteomic analytes from an RBM panel, (2) study whether or not 
combining structural MRI and proteomic data can enhance prediction rates, and (3) employ 
a principled sparse learning method, elastic net logistic regression [5], in the study to 
maximize prediction accuracy while optimizing the selection of disease sensitive 
biomarkers. Our overarching goal is to construct from multimodal data sparse models which 
combine ease of interpretation with high predictive power. The results may provide 
important information about potential surrogate biomarkers for therapeutic trials.
2 Materials and Methods
Data used in this study were obtained from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database (adni.loni.ucla.edu). ADNI is a landmark investigation sponsored by the 
NIH and industrial partners designed to collect longitudinal neuroimaging, biological and 
clinical information from over 800 participants that will track the neural correlates of 
memory loss from an early stage. The following data from 819 ADNI participants were 
downloaded from the ADNI database: all baseline 1.5 T MRI scans, the RBM (Rules-Based 
Medicine) multiplex proteomic analytes extracted from plasma and serum, and demographic 
and baseline diagnosis information. Further information can be found in [15] and at 
www.adni-info.org. For one baseline scan of each participant, FreeSurfer V4 was employed 
to automatically label cortical and subcortical tissue classes [3,4] and to extract target region 
volume and cortical thickness, as well as to extract total intracranial volume (ICV). For each 
hemisphere, thickness measures of 34 cortical regions of interest (ROIs) and volume 
measures of 15 cortical and subcortical ROIs (Fig. 1) were included in this study. Using the 
regression weights derived from the healthy participants, all the FreeSurfer measures were 
adjusted for the baseline age, gender, education, handedness, and ICV, and all the RBM 
proteomic measures were adjusted for the baseline age, gender, education and handedness. 
551 out of 819 participants (57 healthy control (HC), 388 MCI, 106 AD participants) had 
both FreeSurfer and RBM data available. To have a balanced data set among di3erent 
diagnostic groups, we included all HC and AD participants and a randomly selected set of 
110 (out of 388) MCI participants in this study. Their characteristics are summarized in 
Table 1.
Elastic Net
Elastic net logistic regression is a regularized version of logistic regression designed to 
provide good classification performance while employing a minimal number of predictor 
variables. Let yi ∈ {0, 1} denote the class membership of the ith observation and let Xi 
denote the corresponding vector of p classification variables. Elastic net logistic regression 
uses the standard logistic regression model for the dependence of Y on X:
Shen et al. Page 2
Multimodal Brain Image Anal (2011). Author manuscript; available in PMC 2016 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
However, in order to produce sparse classification weight vectors, it estimates β by the 
maximizer of the penalized logistic regression log likelihood function
in which  is the elastic net penalty. Note that 
this penalty function is a convex combination of the L1 lasso penalty and the L2 ridge 
regression penalty. By providing a smooth trade-off between these two penalties, elastic net 
penalization capitalizes on the strengths of both while minimizing their weaknesses; see 
Friedman et al [5] for additional details. The imaging and proteomic biomarker data was 
analyzed using the implementation of elastic net logistic regression provided in the Matlab 
package glmnet.
Experimental Setting
The elastic net is in essence a linear classifier, where logistic regression is just a procedural 
step. For a fair comparison, a linear support vector machine (SVM) [14] coupled with a 
widely used feature selection scheme (SVM-based Recursive Feature Elimination, or SVM-
RFE [6]) was applied in this study. The LIBSVM toolbox was employed to implement SVM 
and SVM-RFE using a linear kernel with default setting. We ran SVM-RFE using the 
training data only to select the top n% features and then trained a SVM classifier using these 
features only. We tested n = 10, 25 and 100, and denoted the corresponding procedures as 
SVM10, SVM25 and SVM (i.e., SVM100, equivalent to no feature selection), respectively. 
For the elastic net, we did three experiments with α = 0.25, 0.5 and 0.75 (to adjust the 
amount of ridge and lasso), respectively, and the parameter λ was tuned by a 10-fold cross-
validation procedure using the training data only. These experiments were applied to three 
data sets: (1) FreeSurfer data (98 variables), (2) RBM data (146 variables), and (3) combined 
FreeSurfer and RBM data (244 variables, a simple concatenation of the two modalities). 
Prediction accuracy was estimated using 5-fold cross-validation.
3 Results
We use EN25, EN50 and EN75 to indicate the elastic net classifiers with α = 0.25, 0.5, and 
0.75, respectively. Table 2 summarizes the 5-fold cross-validation results for classifying HC 
vs AD, HC vs MCI, and MCI vs AD for each combination of six methods (SVM10, SVM25, 
SVM, EN25, EN50 and EN75) and three data sets (FreeSurfer, RBM, combined FreeSurfer 
and RBM). These results are very encouraging in the following sense: (1) Elastic net 
classifiers outperformed SVMs in terms of overall accuracy and area under ROC (AUROC) 
in almost all the cases, while the performances of EN25, EN50 and EN75 did not di3er 
significantly (paired samples test on AUROC p > 0.06 in all cases). (2) The best prediction 
rates using FreeSurfer were 86.6% for HC vs AD and 74.3% for HC vs MCI, comparable 
with the most recent studies using MRI as predictors [7,13,16]. (3) While FreeSurfer data 
performed slightly better in classifying HC vs AD than RBM data, the latter had surprisingly 
greater power to distinguish MCI from HC (87.4%) and AD (83.7%). (4) The combined set 
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consistently outperformed either of FreeSurfer and RBM. While the resulting best prediction 
rate for HC vs AD (91.9%) was competitive with prior multi-modal studies [7,16], the 
prediction rates for HC vs MCI (90.5%) and MCI vs AD (86.5%) significantly exceeded 
results from prior studies that did not use RBM data (e.g., [16]).
Either the SVM or the elastic net classifier can be characterized by a weight vector w, which 
projects each individual data point (i.e., a feature vector) into a 1-D space to produce a 
discriminative value. Each weight measures the strength of the contribution of the 
corresponding feature to the final discriminative value. Elastic net seeks to reduce the 
number of nonzero weights so that only relevant features contribute to the discriminative 
value. For consistency, we always visualize negative weights −w so that larger values (red) 
correspond to lower measurement levels in cases. We show the weight maps (Fig. 1–3) only 
for the combined set analysis, since single modality analyses yielded similar maps.
Shown in Fig. 1 are the weights for the FreeSurfer data. Weights for classifying HC vs AD 
are shown in (a–d) for SVM10, SVM25, SVM and EN50 respectively. While most weights 
were close to zero, EN50 identified a small number of imaging markers known to be AD-
relevant, including hippocampal volume, entorhinal cortex thickness, amygdala volume, and 
so on. Given many blue blocks (i.e., gray matter increase in AD, which is counter-intuitive), 
the SVM map was much less sparse and harder to interpret. While SVM10 and SVM25 
identified a few relevant markers similar to EN50, they also yielded some questionable blue 
blocks and the selected features varied a lot among di3erent cross-validation trials.
Fig. 1(d–f) compare selected features in di3erent classification tasks using EN50. Note that 
Panels (e,f) selected a smaller number of FreeSurfer features even though the overall 
prediction accuracies of all three analyses were comparably high. This might imply that the 
overall prediction accuracies of the latter two tasks (HC vs MCI and MCI vs AD) were more 
dependent on RBM features than FreeSurfer features. These weights can also be back-
projected to the original image space for an intuitive visualization. Fig. 2 shows such a 
visualization for SVM, EN25 and EN50. EN25 and EN50 yield similar maps that are much 
more sparse than the SVM map.
Shown in Fig. 3 are the weight maps for RBM features. Again, EN50 yielded fewer relevant 
features than SVM (see (c–d)). Although SVM10 and SVM25 (see (a–b)) were able to 
identify a few interesting features, the selected features varied a lot among di3erent cross-
validation trials. Using Elastic Net, a number of RBM analytes were found to have altered 
concentrations in AD participants compared to HCs. This is consistent with previous studies 
showing reduced or elevated concentrations of specific analytes in plasma or serum samples 
of AD participants. The trends for some of the identified analytes follow those in the 
published literature and are summarized below. Using a similar RBM panel and 
methodology as done by the ADNI study, O’Bryant et al. identified the analytes alpha-2-
macroglobulin (A2Macro), eotaxin 3 (Eotaxin 3) and pancreatic polypeptide (PPP) to be 
over expressed in the serum of AD participants relative to controls [11] similar to the current 
findings. Elevated plasma concentrations of complement factor H (CFH) and alpha-2-
macroglobulin (A2Macro) [8], reduced plasma concentrations of apolipoprotein AII (ApoA 
II) [9] and elevated serum concentration of apolipoprotein B (ApoB) [2] have been observed 
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in AD participants relative to controls, and these were also found in the present study. 
Apolipoprotein E (ApoE) is a major genetic risk factor for AD [1]. The ApoE concentration 
in the present study was observed to be reduced in AD participants relative to controls. 
There are conflicting reports regarding the serum or plasma concentrations of ApoE protein 
levels in AD, with some studies finding elevated levels, some finding reduced levels and 
others finding no di3erence in levels in AD participants relative to controls [12]. Thus its 
role as a potential AD biomarker is unclear at the present time and needs to be further 
investigated. A number of novel analytes have also been identified to have altered expression 
in AD such as carcinoembryonic antigen (CEA) and pregnancy-associated plasma protein A 
(PA PPA). These analytes may play a role in disease pathology and warrant further 
investigation in independent samples. Thus the identification of novel analytes in addition to 
known analytes demonstrates the power and utility of this approach in identifying potential 
candidate AD biomarkers.
4 Discussion
We have done an integrative analysis of structural MRI data and proteomic data to examine 
their predictive power and identify relevant biomarkers in a large MCI/AD cohort. RBM 
data showed high predictive power to separate MCI from HC and AD. Combining RBM and 
MRI data yielded further improved prediction rates: HC vs AD (91.9%), HC vs MCI 
(90.5%) and MCI vs AD (86.5%), which were competitive to or better than similar prior 
studies. The sparse models generated by elastic net identified a small set of meaningful 
imaging and proteomic biomarkers and were much easier to interpret than SVM-based 
models. The elastic net has great power to optimize the sparsity of feature selection while 
maintaining high predictive power. Its application to multi-modal imaging and biomarker 
data has considerable potential for discovering biomarkers and enhancing mechanistic 
understanding of AD and MCI.
Many identified RBM markers warrant further investigation. Replication in independent 
large samples will be important to confirm these findings. Pathway analysis could be 
performed as a future direction to identify underlying biological pathways of relevant genes 
and proteins. This work was focused on sparse linear classifiers applied to the simple 
concatenation of multi-modal data, since our major goal was to yield easily interpretable 
models while maintaining high predictive power. An initial analysis of applying SVM with a 
radial basis function kernel to the same data yielded comparable or less accurate results, and 
these nonlinear models were much harder to interpret. An interesting future topic is to 
investigate whether these nonlinear models can help improve the prediction rates as well as 
derive biologically meaningful results. Another future direction is to apply multi-kernel 
learning methods (e.g., [7,16]) and see if better predictive models can be achieved and 
relevant biomarkers can be identified.
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Fig. 1. 
Heat maps of classifier weights −w for FreeSurfer measures, where weights were plotted 
against 5 di3erent trials in cross validation tests. Positive values (red) indicate lower 
measurement levels in cases.
Shen et al. Page 7
Multimodal Brain Image Anal (2011). Author manuscript; available in PMC 2016 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Back-projection of negative weights (−w) onto cortical surface, where positive values (red) 
indicate lower measurement levels in cases
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Fig. 3. 
Heat maps of classifier weights −w for RBM measures, where weights were plotted against 
5 di3erent trials in cross validation tests. Positive values (red) indicate lower measurement 
levels in cases.
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Table 1
Participant characteristics
Category HC MCI AD p-value
Gender (M/F) 30/27 60/50 60/46 0.88
Handedness (R/L) 53/4 104/6 99/7 0.91
Baseline Age (years, mean±SD) 75.2±5.8 75.0±7.4 74.8±8.1 0.95
Education (years, mean±SD) 15.7±2.7 15.5±3.0 15.1±3.3 0.37
ICV (cm3, mean±SD) 1506±143 1559±169 1558±195 0.13
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